This year, 125.6 million people tuned in to watch the Seahawks face the Patriots in the Super Bowl. While the game was the main draw, it's perhaps the one time of year that commercials generate equal excitement. 2026 was no exception, but before the first quarter ended, it was clear which industry dominated the 2026 ad buys: artificial intelligence. AI has become ubiquitous in daily life, and there's almost no industry that hasn't been impacted by its adoption, including nuclear medicine. While some of its applications are clear, questions remain about how AI will be used in clinical settings, patient interactions, image interpretation, and more. On this episode of the SNMMI Podcast, Lance Burrell moderates a discussion with Dmitry Beyer, MPA, CNMT, and Samantha Heasty on AI and its capabilities, potential, and shortcomings. Tune in now!

This episode of the SNMMI Podcast is sponsored by GE Healthcare.

Important Safety Information – VIZAMYL

PRODUCT INDICATIONS AND USE

VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:

· Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline

· Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.

CONTRAINDICATIONS

VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

So much of what we know about heart health is based on male models. Classic heart attack symptoms describe the experiences of men, drugs were developed largely by men for men—even in research, mouse models were male. But in recent years, our understanding of women's cardiac health has expanded, and critically, we have learned that we cannot simply apply male models to female patients. As one of our guests says, "women are not small men." For American Heart Month, join us for a heart-to-heart with members of the SNMMI Cardiovascular Council as they discuss how nuclear cardiology is providing new insight into women's heart health. Listen here or wherever you stream your podcasts.

This episode of the SNMMI Podcast is sponsored by GE Healthcare.

Important Safety Information – VIZAMYL

PRODUCT INDICATIONS AND USE

VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:

· Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline

· Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.

CONTRAINDICATIONS

VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

Join Phillip Kuo, MD, PhD, and Jacob Dubroff, MD, PhD as they delve into discussions about the latest tracers, brain imaging techniques, and advances in patient care.

To learn more about advancements in neurology in nuclear medicine, register for the upcoming SNMMI Mid-Winter Meeting with a dedicated neurology track. Register Here: https://snmmi.org/MWM/MWM/Attend/Register.aspx

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

Join Lance Burrell for a continued conversation on nuclear medicine physicians of the future with Munir Ghesani, MD and Jean-Luc Urbain, MD, PhD. Together, they cover the medical student curriculum, current programs available, and the future of nuclear medicine.

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

Join Lance Burrell for an insightful conversation with Dr. Gary Ulaner, as they discuss the role of nuclear medicine in breast cancer treatment and lesser-known breast cancer types.

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

Join Dr. Faraz Farhadi and Dr. Navid Hasani as they discuss solutions to recruiting nuclear medicine physicians and expanding the pipeline of trainees.

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

This podcast is brought to you by Lilly, member of the SNMMI Value Initiative Industry Alliance. Hosts Anupa Arora, MD and Anthony “Nino” Sireci, MD discuss a New Era in Alzheimer Diagnostics. This episode takes a focused look at high-impact topics shaping the future of Nuclear Medicine and Molecular Imaging, designed specifically for professionals driving value in the field.

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X

June is Alzheimer's and Brain Awareness month, join Phillip Kuo, MD, PhD as he delves into the history of neurodegenerative disorders and the progress nuclear medicine has made to help diagnose and treat diseases like dementia and Alzheimer’s.

Want more SNMMI content? Follow us on:

YouTube | Instagram | LinkedIn | Twitter/X